Prostate Cancer Clinical Trial
Official title:
Single Site, Phase II, Double Blind, Randomized, Placebo Controlled Study of the Effect of Dutasteride (Avodart) 0.5mg on the Volume and Characteristics of Prostate Cancer, as Assessed by Multifunctional Magnetic Resonance Imaging (MRI) With Lower Risk Prostate Cancer Suitable for Active Surveillance. (MAPPED TRIAL)
Verified date | August 2011 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | Unspecified |
Study type | Interventional |
RATIONALE: Dutasteride may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This randomized phase II trial is studying how well giving dutasteride works in
treating patients with prostate cancer.
Status | Recruiting |
Enrollment | 42 |
Est. completion date | |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | N/A to 80 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed prostate cancer, meeting all of the following criteria: - Prostate-specific antigen (PSA) < 10.0 ng/mL - T1c-T2a disease - Gleason sum of 6 or 7 (secondary pattern 4 only) - Patients with low risk disease must meet the following criteria: - Gleason pattern 3 + 3 - PSA < 10.0 ng/mL - Clinical T2a disease - Patients with Gleason secondary pattern 4 (i.e., Gleason Pattern 3 + 4) are eligible but must not have a primary pattern 4, PSA > 10 ng/mL, or clinical T2b disease - Measurable disease on MRI of at least 0.2 cc, based on planimetry volume - Biopsy-proven disease within 2 years of screening visit - No biopsy artifact on MRI scan (minimum 12-week interval between biopsy and baseline MRI) - Eligible for active surveillance according to the criteria set out by the National Institute for Health and Clinical Excellence PATIENT CHARACTERISTICS: - ALT and AST = 2 times the upper limit of normal (ULN) - Alkaline phosphatase = 2 times ULN - Bilirubin = 1.5 times ULN - Estimated glomerular filtration rate (eGFR) = 60 mL/min - Able to swallow and retain oral medication - Able and willing to participate in the study for its duration - Able to read and write (health-outcomes questionnaires are written) - Able to understand instructions related to study procedures and give written informed consent - No history of another malignancy within five years that could affect the diagnosis of prostate cancer - No history or current evidence of drug or alcohol abuse within the last 12 months that might confound the results of the study or pose additional risk to the patient - No known hypersensitivity to any 5a-reductase inhibitor or to any drug chemically related to dutasteride - No contraindication for undergoing gadolinium-enhanced MRI, including any of the following: - Inability to see tumor focus of = 0.2 cc on T2 sequences - Previous allergic reaction to gadolinium - Serum creatinine > ULN - Incompatible pacemaker - Metal fragments in eyes - Hip replacements that give artifact with prostate/pelvis views - Any artifact or condition that reduces image quality of MRI (e.g., inability to keep still) - No unstable serious co-existing medical condition(s) including, but not limited, to any of the following: - Myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 6 months prior to screening visit - Uncontrolled diabetes - Peptic ulcer disease uncontrolled by medical management PRIOR CONCURRENT THERAPY: - No prior radiotherapy (external-beam or brachytherapy), high-intensity focused ultrasound (HIFU), or photodynamic therapy (PDT) - No prior chemotherapy - At least 3 months since prior and no concurrent prostatic surgery, including TUNA, TURP, TUIP, laser treatment, thermotherapy, balloon dilatation, prosthesis, and ultrasound ablation - No prior oral glucocorticoids - Glucocorticoids, except inhaled or topical, are not permitted within 3 months prior to visit one - No prior GnRH analogues (e.g., leuprolide, goserelin) - No prior or concurrent hormonal treatment (e.g., megestrol, medroxyprogesterone, cyproterone, DES) of prostate cancer - No current and/or prior use of the following medications: - Finasteride (Proscar, Propecia), or dutasteride (GI198745, AVODART) exposure within 12 months prior to study entry - Any other investigational 5a-reductase inhibitors within the past 12 months - Anabolic steroids within the past 6 months - Drugs with antiandrogenic properties within the past 6 months (e.g., spironolactone, flutamide, bicalutamide, cimetidine, ketoconazole, progestational agents) - The use of cimetidine is permitted prior to study entry - The use of topical ketoconazole is permitted prior to and during the study - No participation in another investigational or marketed drug trial within the 30 days prior to the first dose of study drug or anytime during the study period |
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | University College of London Hospitals | London | England |
Lead Sponsor | Collaborator |
---|---|
University College London Hospitals |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change in volume of foci of prostate cancer (PC) as assessed by T2-weighted (T2w) MRI between baseline and 6 months | No | ||
Secondary | The change in volume of PC as determined by gadolinium-enhanced (GE) MRI and diffusion-weighted (DW) MRI at 6 months | No | ||
Secondary | The change in volume of PC as determined by T2w MRI, GE MRI, and DW MRI at 3 months | No | ||
Secondary | The changes in MR characteristics of PC (perfusion, cell density) between baseline and 6 months | No | ||
Secondary | The change in volume of PC as assessed by HistoScan transrectal ultrasound (TRUS) between baseline and 6 months | No | ||
Secondary | The association between the measured PC volumes on MRI with the measured PC volumes on TRUS at baseline and 6 months | No | ||
Secondary | The association between the measured changes in PC volume using MRI vs TRUS at baseline and 6 months | No | ||
Secondary | The association of PC volume change with qualitative changes seen on TRUS between baseline and 6 months | No | ||
Secondary | The association between MR changes in volume and characteristics with histological features as seen on 6-month biopsy (Gleason score and sum, number of cores involved, cancer core length) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |